A Phase I Randomised, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of WD-910 in Healthy Participants
Latest Information Update: 04 Apr 2025
At a glance
- Drugs WD 910 (Primary)
- Indications Dementia; Multiple sclerosis
- Focus Adverse reactions; Pharmacokinetics
- 04 Apr 2025 New trial record